Table 2. Projected Annual Out-of-Pocket Expenses in First Available Year vs 2019.

Product	First available year (2010-2019)	Projected annual out-of-pocket cost, $		Change in annual out-of-pocket costs from first available year to 2019, $
		First available year, 2010-2018	2019
Certolizumab pegol, 200 mg	2010	6108	4710	−1398
Etanercept
25 mg	2010	5647	3593	−2054
50 mg/1 mL	2010	6254	5168	−1086
Adalimumab
20 mg/0.4 mL	2010	6177	5196	−981
40 mg/0.8 mL	2010	6177	5168	−1009
Golimumab, 50 mg/0.5 mL	2010	6282	4967	−1315
Certolizumab pegol, 200 mg/1 mL	2011	4046	4676	630
Abatacept, 125 mg/1 mL	2012	4317	4625	308
Tofacitinib, 5 mg	2014	4218	4787	569
Tocilizumab, 162 mg/0.9 mL	2015	3225	2618	−607
Golimumab, 100 mg/1 mL	2015	5067	5439	372
Adalimumab, 10 mg/0.2 mL	2016	5290	5202	−88
Tofacitinib, extended-release 11 mg	2017	5025	4765	−260
Sarilumab
150 mg/1.14 mL	2018	4524	4075	−449
200 mg/1.14 mL	2018	4524	4075	−449
Abatacept
50 mg/0.4 mL	2018	5179	4682	−497
87.5 mg/0.7 mL	2018	5179	4682	−497